CD19 and graft versus host disease: Infusion of human leukocyte antigen-mismatched anti-CD19 CAR-NK cells derived from cord blood does not cause cytokine release syndrome, neurotoxicity, or GvHD in patients with CD19+ relapsed or refractory lymphoma or leukemia.